Company: SION
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001193125-25-022709
Chunk: 142

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-07
Form: 424B4
Chunk 142
---
 including the costs associated with operating as a public company following the completion of this offering. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings or strategic agreements. To date, we have funded our operations primarily from the sale of proceeds of preferred stock. As of September 30, 2024, we had received aggregate net proceeds of $330.4 million from the sale of our preferred stock in private placements. As of September 30, 2024, we had $180.9 million in cash, cash equivalents and marketable securities. Cash Flows The following table sets forth a summary of the net cash flow activity (in thousands):

|                                                                       | 2024 | Nine Months Ended 
 September 30,     |          |   | 2023 |   |         |   | 2023 | Year Ended December 31, |         |   | 2022 |   |         |   |
|:----------------------------------------------------------------------|:-----|:------------------|---------:|:--|:-----|:--|--------:|:--|:-----|:------------------------|--------:|:--|:-----|:--|--------:|:--|
| Net cash used in operating activities                                 |      | $                 |  (41,006 | ) |      | $ | (36,247 | ) |      | $                       | (43,699 | ) |      | $ | (36,068 | ) |
| Net cash (used in) provided by investing activities                   |      |                   | (142,141 | ) |      |   |  20,224 |   |      |                         |  27,352 |   |      |   | (29,263 | ) |
| Net cash provided by financing activities                             |      |                   |  180,375 |   |      |   |      31 |   |      |                         |      31 |   |      |   | 110,855 |   |
| Net (decrease) increase in cash, cash equivalents and restricted cash |      | $                 |   (2,772 | ) |      | $ | (15,992 | ) |      | $                       | (16,316 | ) |      | $ |  45,524 |   |

Operating Activities For the nine months ended September 30, 2024, net cash used in operating activities was $41.0 million